



ELSEVIER

Diabetes Research and Clinical Practice 48 (2000) 225–227

DIABETES RESEARCH
AND
CLINICAL PRACTICE

www.elsevier.com/locate/diabres

Author index of volume 48

- Åberg, A., see Agardh, E. 48, 61
Agardh, C.-D., see Agardh, E. 48, 61
Agardh, E., A. Herbst, A. Åberg, C.-D. Agardh, Fetal growth is not associated with early onset of severe retinopathy in type 1 diabetes mellitus 48, 61
Akiyama, M., see Nagaia, T. 48, 99
Aoki, S.-i., G. Hasegawa, H. Shigeta, H. Obayashi, M. Fujii, F. Kimura, A. Moriwaki, N. Nakamura, K. Ienaga, K. Nakamura, M. Kondo, Crossline levels in serum and erythrocyte membrane proteins from patients with diabetic nephropathy 48, 119
Araki, E., see Motoshima, H. 48, 155
Araki, E., see Wake, N. 48, 201
Aso, Y., see Inukai, T. 48, 23
Attardo, T., see Sangiorgio, L. 48, 147
Azriel, S., see Campos-Pastor, M.M. 48, 43

Barone, M., see Sangiorgio, L. 48, 147
Blades, B.L., see Donaghue, K.C. 48, 193
Brosh, D., see Rachmani, R. 48, 139

Campos-Pastor, M.M., F. Escobar-Jiménez, P. Mezquita, J.L. Herrera-Pombo, F. Hawkins-Carranza, J.D. Luna, S. Azriel, A. Serrallara, M. Rigopoulos, Factors associated with microalbuminuria in Type 1 diabetes mellitus: a cross-sectional study 48, 43
Chakrabarti, S., see Evans, T. 48, 75
Chamukuttan, S., see Viswanathan, V. 48, 211
Chan, A.K.F., see Donaghue, K.C. 48, 193
Chen, Y., W.X. Liao, A.C. Roy, A. Loganath, S.C. Ng, Mitochondrial gene mutations in gestational diabetes mellitus 48, 29

Dobashi, K., see Nagaia, T. 48, 99
Dohi, K., see Kanauchi, M. 48, 113
Donaghue, K.C., M.M. Pena, A.K.F. Chan, B.L. Blades, J. King, L.H. Storlien, M. Silink, Beneficial effects of increasing monounsaturated fat intake in adolescents with type 1 diabetes 48, 193

Downey, D., see Evans, T. 48, 75

Ehara, M., see Sasakuma, F. 48, 105
Escobar-Jiménez, F., see Campos-Pastor, M.M. 48, 43
Evans, T., D. Xi Deng, K. Mukherjee, D. Downey, S. Chakrabarti, Endothelins, their receptors, and retinal vascular dysfunction in galactose-fed rats 48, 75

Fujii, M., see Aoki, S.-i. 48, 119
Fujii, M., see Miyatake, N. 48, 15
Fujiwara, Y., see Inukai, T. 48, 23
Fukuharu, M., J. Sato, I. Ohsawa, Y. Oshida, M. Nagasaki, N. Nakai, Y. Shimomura, M. Hattori, S. Tokudome, Y. Sato, Additive effects of estrogen deficiency and diabetes on bone mineral density in rats 48, 1

Gangemi, R., see Sangiorgio, L. 48, 147


Haneda, M., see Nakagawa, H. 48, 87
Hasegawa, G., see Aoki, S.-i. 48, 119
Hattori, M., see Fukuharu, M. 48, 1
Hawkins-Carranza, F., see Campos-Pastor, M.M. 48, 43
Hazama, F., see Nakagawa, H. 48, 87
Herbst, A., see Agardh, E. 48, 61
Herrera-Pombo, J.L., see Campos-Pastor, M.M. 48, 43
Hirashima, Y., see Motoshima, H. 48, 155
Hisashige, A., see Wake, N. 48, 201

Ienaga, K., see Aoki, S.-i. 48, 119
Inukai, T., Y. Fujiwara, K. Tayama, Y. Aso, Y. Takemura, Serum levels of carboxy-terminal propeptide of human type I procollagen are an indicator for the progression of diabetic nephropathy in patients with Type 2 diabetes mellitus 48, 23
Ishida, H., see Suzuki, K. 48, 185
Ishizuka, S., see Suzuki, K. 48, 185

Kanauchi, M., T. Kawano, K. Dohi, Serum IgA levels in patients with diabetic nephropathy and IgA nephropathy superimposed on diabetes mellitus 48, 113

- Kaneko, K., see Motoshima, H. 48, 155
 Kashiwagi, A., see Maeno, Y. 48, 127
 Katayama, T., see Wake, N. 48, 201
 Kawano, T., see Kanauchi, M. 48, 113
 Kawashima, J., see Motoshima, H. 48, 155
 Kikkawa, R., see Maeno, Y. 48, 127
 Kikkawa, R., see Nakagawa, H. 48, 87
 Kikuyama, M., see Suzuki, K. 48, 185
 Kimura, F., see Aoki, S.-i. 48, 119
 Kimura, I., see Miyatake, N. 48, 15
 King, J., see Donaghue, K.C. 48, 193
 Kishikawa, H., see Motoshima, H. 48, 155
 Kishikawa, H., see Wake, N. 48, 201
 Kobayashi, K.-i., see Ohta, M.Y. 48, 171
 Kodama, K., see Nakazato, M. 48, 177
 Kondo, M., see Aoki, S.-i. 48, 119
 Koya, D., see Nakagawa, H. 48, 87
- Lavanya, A., see Shobhana, R. 48, 37
 Levi, Z., see Rachmani, R. 48, 139
 Liao, W.X., see Chen, Y. 48, 29
 Lidar, M., see Rachmani, R. 48, 139
 Loganath, A., see Chen, Y. 48, 29
 Luna, J.D., see Campos-Pastor, M.M. 48, 43
 Lunetta, M., see Sangiorgio, L. 48, 147
- Maeno, Y., A. Kashiwagi, Y. Nishio, N. Takahara, R. Kikkawa, IDL can stimulate atherogenic gene expression in cultured human vascular endothelial cells 48, 127
 Makino, H., see Miyatake, N. 48, 15
 Mezquita, P., see Campos-Pastor, M.M. 48, 43
 Miglani, S., A. Sood, P. Shah, Self reported attitude and behavior of young diabetics about discussing their disease 48, 9
 Mita, Y., see Nagaia, T. 48, 99
 Miyamoto, S., see Nakazato, M. 48, 177
 Miyatake, N., M. Fujii, H. Nishikawa, J. Wada, K. Shikata, H. Makino, I. Kimura, Clinical evaluation of muscle strength in 20-79-years-old obese Japanese 48, 15
 Morii, T., see Sasakuma, F. 48, 105
 Mori, M., see Nagaia, T. 48, 99
 Moriwaki, A., see Aoki, S.-i. 48, 119
 Motoshima, H., E. Araki, T. Nishiyama, T. Taguchi, K. Kaneko, Y. Hirashima, K. Yoshizato, A. Shirakami, K. Sakai, J. Kawashima, T. Shirotani, H. Kishikawa, M. Shichiri, Bradykinin enhances insulin receptor tyrosine kinase in 32D cells reconstituted with bradykinin and insulin signaling pathways 48, 155
 Mukherjee, K., see Evans, T. 48, 75
- Nagaia, T., M. Akiyama, Y. Mita, T. Tomizawa, K. Dobashi, M. Mori, Mycobacterium avium complex pleuritis accompanied by diabetes mellitus 48, 99
 Nagai, Y., see Ohta, M.Y. 48, 171
 Nagasaki, M., see Fukuharu, M. 48, 1
 Nakagawa, H., M. Sasahara, M. Haneda, D. Koya, F. Hazama, R. Kikkawa, Immunohistochemical characterization of glomerular PDGF B-chain and PDGF β -receptor expression in diabetic rats 48, 87
 Nakai, N., see Fukuharu, M. 48, 1
 Nakamura, K., see Aoki, S.-i. 48, 119
 Nakamura, N., see Aoki, S.-i. 48, 119
 Nakazato, M., K. Kodama, S. Miyamoto, M. Sato, T. Sato, Psychiatric disorders in juvenile patients with insulin-dependent diabetes mellitus 48, 177
 Ng, S.C., see Chen, Y. 48, 29
 Nishikawa, H., see Miyatake, N. 48, 15
 Nishio, Y., see Maeno, Y. 48, 127
 Nishiyama, T., see Motoshima, H. 48, 155
 Nohara, E., see Ohta, M.Y. 48, 171
 Nosaka, K., see Suzuki, K. 48, 185
- Obayashi, H., see Aoki, S.-i. 48, 119
 Ohkubo, Y., see Wake, N. 48, 201
 Ohsawa, I., see Fukuharu, M. 48, 1
 Ohta, M.Y., Y. Nagai, T. Takamura, E. Nohara, K.-i. Kobayashi, Inhibitory effect of troglitazone on TNF- α -induced expression of monocyte chemoattractant protein-1 (MCP-1) in human endothelial cells 48, 171
 Oshida, Y., see Fukuharu, M. 48, 1
- Pena, M.M., see Donaghue, K.C. 48, 193
 Prasad, D., see Viswanathan, V. 48, 211
- Rachmani, R., M. Lidar, D. Brosh, Z. Levi, M. Ravid, Oxidation of low-density lipoprotein in normotensive type 2 diabetic patients. Comparative effects of enalapril versus nifedipine: a randomized cross-over study 48, 139
 Ramachandran, A., C. Snehalatha, R. Sasikala, K. Satyavani, V. Vijay, Vascular complications in young Asian Indian patients with Type 1 diabetes mellitus 48, 51
 Ramachandran, A., see Shobhana, R. 48, 37
 Ramachandran, A., see Snehalatha, C. 48, 57
 Ramachandran, A., see Viswanathan, V. 48, 211
 Rama Rao, P., see Shobhana, R. 48, 37
 Ravid, M., see Rachmani, R. 48, 139
 Rigopoulos, M., see Campos-Pastor, M.M. 48, 43
 Roy, A.C., see Chen, Y. 48, 29
 Rubino, C., see Sangiorgio, L. 48, 147
- Sakai, K., see Motoshima, H. 48, 155
 Sakai, M., see Wake, N. 48, 201
 Sangiorgio, L., T. Attardo, R. Gangemi, C. Rubino, M. Barone, M. Lunetta, Increased frequency of HCV and HBV infection in type 2 diabetic patients 48, 147
 Sasahara, M., see Nakagawa, H. 48, 87
 Sasaki, A., see Sasakuma, F. 48, 105
 Sasakuma, F., T. Shimizu, H. Wada, T. Morii, A. Sasaki, M. Ehara, Human anti-murine antibodies interfere with CPR assays performed with commercial kits 48, 105
 Sasikala, R., see Ramachandran, A. 48, 51
 Sato, J., see Fukuharu, M. 48, 1
 Sato, M., see Nakazato, M. 48, 177
 Sato, T., see Nakazato, M. 48, 177

- Sato, Y., see Fukuharu, M. 48, 1
- Satyavani, K., see Ramachandran, A. 48, 51
- Satyavani, K., see Snehalatha, C. 48, 57
- Seino, Y., see Suzuki, K. 48, 185
- Serraclara, A., see Campos-Pastor, M.M. 48, 43
- Shah, P., see Miglani, S. 48, 9
- Shichiri, M., see Motoshima, H. 48, 155
- Shichiri, M., see Wake, N. 48, 201
- Shigeta, H., see Aoki, S.-i. 48, 119
- Shikata, K., see Miyatake, N. 48, 15
- Shimizu, T., see Sasakuma, F. 48, 105
- Shimomura, Y., see Fukuharu, M. 48, 1
- Shirakami, A., see Motoshima, H. 48, 155
- Shirohani, T., see Motoshima, H. 48, 155
- Shobhana, R., P. Rama Rao, A. Lavanya, R. Williams, V. Vijay, A. Ramachandran, Expenditure on health care incurred by diabetic subjects in a developing country — a study from southern India 48, 37
- Silink, M., see Donaghue, K.C. 48, 193
- Simmons, D., see Yapa, M. 48, 217
- Sivasankari, S., see Snehalatha, C. 48, 57
- Snehalatha, C., see Ramachandran, A. 48, 51
- Snehalatha, C., S. Sivasankari, K. Satyavani, V. Vijay, A. Ramachandran, Postprandial hypertriglyceridaemia in treated type 2 diabetic subjects — the role of dietary components 48, 57
- Sood, A., see Miglani, S. 48, 9
- Storlien, L.H., see Donaghue, K.C. 48, 193
- Sugimoto, C., see Suzuki, K. 48, 185
- Suzuki, K., C. Sugimoto, M. Takizawa, S. Ishizuka, M. Kikuyama, H. Togawa, Y. Taguchi, K. Nosaka, Y. Seino, H. Ishida, Correlations between bone mineral density and circulating bone metabolic markers in diabetic patients 48, 185
- Taguchi, T., see Motoshima, H. 48, 155
- Taguchi, Y., see Suzuki, K. 48, 185
- Takahara, N., see Maeno, Y. 48, 127
- Takamura, T., see Ohta, M.Y. 48, 171
- Takemura, Y., see Inukai, T. 48, 23
- Takizawa, M., see Suzuki, K. 48, 185
- Tayama, K., see Inukai, T. 48, 23
- Togawa, H., see Suzuki, K. 48, 185
- Tokudome, S., see Fukuharu, M. 48, 1
- Tomizawa, T., see Nagaia, T. 48, 99
- Vijay, V., see Ramachandran, A. 48, 51
- Vijay, V., see Shobhana, R. 48, 37
- Vijay, V., see Snehalatha, C. 48, 57
- Viswanathan, V., D. Prasad, S. Chamukuttan, A. Ramachandran, High prevalence and early onset of cardiac autonomic neuropathy among South Indian Type 2 diabetic patients with nephropathy 48, 211
- Wada, H., see Sasakuma, F. 48, 105
- Wada, J., see Miyatake, N. 48, 15
- Wake, N., A. Hisashige, T. Katayama, H. Kishikawa, Y. Ohkubo, M. Sakai, E. Araki, M. Shichiri, Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study 48, 201
- Williams, R., see Shobhana, R. 48, 37
- Xi Deng, D., see Evans, T. 48, 75
- Yapa, M., D. Simmons, Screening for gestational diabetes mellitus in a multiethnic population in New Zealand 48, 217
- Yoshizato, K., see Motoshima, H. 48, 155



Subject index of volume 48

Adolescents; Monounsaturated fats; *n*-9 Fatty acids; Insulin-dependent diabetes mellitus **48, 193**

Advanced glycation endproduct; Diabetic nephropathy; Crossline **48, 119**

Asian Indians; Triglycerides; Postprandial lipaemia; High carbohydrate diet; Type 2 diabetes **48, 57**

Asian Indians; Type 1 diabetes; Complications; Retinopathy; Nephropathy; Neuropathy; Coronary heart diseases **48, 51**

Atherosclerosis; Intermediate density lipoprotein; Monocyte chemoattractant protein-1; Diabetes mellitus **48, 127**

Behavior; Diabetes of young; Disclosure; Education **48, 9**

Birth weight; Fetal growth; Severe retinopathy; Type 1 diabetes **48, 61**

Body composition; Obesity; Grip strength; Leg strength; Weight bearing index **48, 15**

Bone density; Rats; Ovariectomy; Diabetes; Osteoporosis **48, 1**

Bone mineral density; Computed X-ray densitometry; Non-insulin-dependent diabetes mellitus; Cortical bone; Diabetic retinopathy; Parathyroid hormone; Calcium; Parathyroid hormone-related peptide **48, 185**

Bradykinin B2 receptor; Insulin receptor; IRS-1; PI 3-kinase; Protein tyrosine phosphatase **48, 155**

Calcium; Computed X-ray densitometry; Non-insulin-dependent diabetes mellitus; Bone mineral density; Cortical bone; Diabetic retinopathy; Parathyroid hormone; Parathyroid hormone-related peptide **48, 185**

Cardiac autonomic neuropathy; Type 2 diabetes; Nephropathy; Neuropathy **48, 211**

Cehular immunity; Malnutrition; Microvascular circulation; Diabetic nephropathy **48, 99**

Complications; Type 1 diabetes; Asian Indians; Retinopathy; Nephropathy; Neuropathy; Coronary heart diseases **48, 51**

Computed X-ray densitometry; Non-insulin-dependent diabetes mellitus; Bone mineral density; Cortical bone; Diabetic retinopathy; Parathyroid hormone; Calcium; Parathyroid hormone-related peptide **48, 185**

Coronary heart diseases; Type 1 diabetes; Complications; Asian Indians; Retinopathy; Nephropathy; Neuropathy **48, 51**

Cortical bone; Computed X-ray densitometry; Non-insulin-dependent diabetes mellitus; Bone mineral density; Diabetic retinopathy; Parathyroid hormone; Calcium; Parathyroid hormone-related peptide **48, 185**

Cost-effectiveness; Type 2 diabetes; Microvascular complications; Intensive glycemic control; Multiple insulin injection treatment **48, 201**

C-peptide; HAMA; Immunoassay; Interference **48, 105**

Crossline; Diabetic nephropathy; Advanced glycation end-product **48, 119**

Developing country; Health economics; Diabetes health care; Economic burden; Direct costs; Expenses by patients; India **48, 37**

Diabetes; Bone density; Rats; Ovariectomy; Osteoporosis **48, 1**

- Diabetes health care;** Health economics; Economic burden; Direct costs; Expenses by patients; Developing country; India 48, 37
- Diabetes mellitus;** Intermediate density lipoprotein; Atherosclerosis; Monocyte chemoattractant protein-1 48, 127
- Diabetes of young;** Behavior; Disclosure; Education 48, 9
- Diabetic nephropathy;** Crossline; Advanced glycation end-product 48, 119
- Diabetic nephropathy;** Familial hypertension; Familial nephropathy 48, 43
- Diabetic nephropathy;** Immunoglobulin A nephropathy; Renal biopsy 48, 113
- Diabetic nephropathy;** Malnutrition; Cellular immunity; Microvascular circulation 48, 99
- Diabetic nephropathy;** Platelet-derived growth factor; Immunohistochemistry; Mesangial cells; Visceral epithelial cells 48, 87
- Diabetic nephropathy;** Type I procollagen; Diabetic retinopathy; Osteocalcin; Type 2 diabetes 48, 23
- Diabetic retinopathy;** Computed X-ray densitometry; Non-insulin-dependent diabetes mellitus; Bone mineral density; Cortical bone; Parathyroid hormone; Calcium; Parathyroid hormone-related peptide 48, 185
- Diabetic retinopathy;** Endothelins; Endothelin receptors galactosemia; Retinal blood flow 48, 75
- Diabetic retinopathy;** Type I procollagen; Diabetic nephropathy; Osteocalcin; Type 2 diabetes 48, 23
- Direct costs;** Health economics; Diabetes health care; Economic burden; Expenses by patients; Developing country; India 48, 37
- Disclosure;** Diabetes of young; Behavior; Education 48, 9
- Economic burden;** Health economics; Diabetes health care; Direct costs; Expenses by patients; Developing country; India 48, 37
- Education;** Diabetes of young; Behavior; Disclosure 48, 9
- Endothelial cells;** MCP-1; Troglitazone; TNF- α 48, 171
- Endothelin receptors galactosemia;** Diabetic retinopathy; Endothelins; Retinal blood flow 48, 75
- Endothelins;** Diabetic retinopathy; Endothelin receptors galactosemia; Retinal blood flow 48, 75
- Expenses by patients;** Health economics; Diabetes health care; Economic burden; Direct costs; Developing country; India 48, 37
- Familial hypertension;** Diabetic nephropathy; Familial nephropathy 48, 43
- Familial nephropathy;** Diabetic nephropathy; Familial hypertension 48, 43
- Fetal growth;** Birth weight; Severe retinopathy; Type 1 diabetes 48, 61
- GDM;** Mitochondrial DNA; Mutations; tRNA-Leu; ND1 gene 48, 29
- Gestational diabetes;** Screening; Polynesian 48, 217
- Grip strength;** Obesity; Leg strength; Weight bearing index; Body composition 48, 15
- HAMA;** C-peptide; Immunoassay; Interference 48, 105
- HBV infection;** HCV infection; Type 2 diabetes; Transaminases 48, 147
- HCV infection;** HBV infection; Type 2 diabetes; Transaminases 48, 147
- Health economics;** Diabetes health care; Economic burden; Direct costs; Expenses by patients; Developing country; India 48, 37
- High carbohydrate diet;** Triglycerides; Postprandial lipaemia; Asian Indians; Type 2 diabetes 48, 57
- Immunoassay;** C-peptide; HAMA; Interference 48, 105
- Immunoglobulin A nephropathy;** Diabetic nephropathy; Renal biopsy 48, 113
- Immunohistochemistry;** Platelet-derived growth factor; Diabetic nephropathy; Mesangial cells; Visceral epithelial cells 48, 87
- India;** Health economics; Diabetes health care; Economic burden; Direct costs; Expenses by patients; Developing country 48, 37
- Insulin-dependent diabetes mellitus;** Adolescents; Monounsaturated fats; *n*-9 Fatty acids 48, 193
- Insulin-dependent diabetes mellitus;** Psychiatric disorders; Metabolic control; Psychosocial functioning 48, 177
- Insulin receptor;** Bradykinin B2 receptor; IRS-1; PI 3-kinase; Protein tyrosine phosphatase 48, 155

- Intensive glycemic control;** Type 2 diabetes; Microvascular complications; Multiple insulin injection treatment; Cost-effectiveness 48, 201
- Interference;** C-peptide; HAMA; Immunoassay 48, 105
- Intermediate density lipoprotein;** Atherosclerosis; Monocyte chemoattractant protein-1; Diabetes mellitus 48, 127
- IRS-1;** Bradykinin B2 receptor; Insulin receptor; PI 3-kinase; Protein tyrosine phosphatase 48, 155
- Leg strength;** Obesity; Grip strength; Weight bearing index; Body composition 48, 15
- Malnutrition;** Cellular immunity; Microvascular circulation; Diabetic nephropathy 48, 99
- MCP-1;** Endothelial cells; Troglitazone; TNF- α 48, 171
- Mesangial cells;** Platelet-derived growth factor; Diabetic nephropathy; Immunohistochemistry; Visceral epithelial cells 48, 87
- Metabolic control;** Insulin-dependent diabetes mellitus; Psychiatric disorders; Psychosocial functioning 48, 177
- Microvascular circulation;** Malnutrition; Cellular immunity; Diabetic nephropathy 48, 99
- Microvascular complications;** Type 2 diabetes; Intensive glycemic control; Multiple insulin injection treatment; Cost-effectiveness 48, 201
- Mitochondrial DNA;** GDM; Mutations; tRNA-Leu; ND1 gene 48, 29
- Monocyte chemoattractant protein-1;** Intermediate density lipoprotein; Atherosclerosis; Diabetes mellitus 48, 127
- Monounsaturated fats;** Adolescents; *n*-9 Fatty acids; Insulin-dependent diabetes mellitus 48, 193
- Multiple insulin injection treatment;** Type 2 diabetes; Microvascular complications; Intensive glycemic control; Cost-effectiveness 48, 201
- Mutations;** Mitochondrial DNA; GDM; tRNA-Leu; ND1 gene 48, 29
- ND1 gene;** Mitochondrial DNA; GDM; Mutations; tRNA-Leu 48, 29
- Nephropathy;** Type 2 diabetes; Cardiac autonomic neuropathy; Neuropathy 48, 211
- Nephropathy;** Type 1 diabetes; Complications; Asian Indians; Retinopathy; Neuropathy; Coronary heart diseases 48, 51
- Neuropathy;** Type 2 diabetes; Cardiac autonomic neuropathy; Nephropathy 48, 211
- Neuropathy;** Type 1 diabetes; Complications; Asian Indians; Retinopathy; Nephropathy; Coronary heart diseases 48, 51
- n*-9 Fatty acids;** Adolescents; Monounsaturated fats; Insulin-dependent diabetes mellitus 48, 193
- Non-insulin-dependent diabetes mellitus;** Computed X-ray densitometry; Bone mineral density; Cortical bone; Diabetic retinopathy; Parathyroid hormone; Calcium; Parathyroid hormone-related peptide 48, 185
- Obesity;** Grip strength; Leg strength; Weight bearing index; Body composition 48, 15
- Osteocalcin;** Type I procollagen; Diabetic nephropathy; Diabetic retinopathy; Type 2 diabetes 48, 23
- Osteoporosis;** Bone density; Rats; Ovariectomy; Diabetes 48, 1
- Ovariectomy;** Bone density; Rats; Diabetes; Osteoporosis 48, 1
- Parathyroid hormone;** Computed X-ray densitometry; Non-insulin-dependent diabetes mellitus; Bone mineral density; Cortical bone; Diabetic retinopathy; Calcium; Parathyroid hormone-related peptide 48, 185
- Parathyroid hormone-related peptide;** Computed X-ray densitometry; Non-insulin-dependent diabetes mellitus; Bone mineral density; Cortical bone; Diabetic retinopathy; Parathyroid hormone; Calcium 48, 185
- PI 3-kinase;** Bradykinin B2 receptor; Insulin receptor; IRS-1; Protein tyrosine phosphatase 48, 155
- Platelet-derived growth factor;** Diabetic nephropathy; Immunohistochemistry; Mesangial cells; Visceral epithelial cells 48, 87
- Polynesian;** Gestational diabetes; Screening 48, 217
- Postprandial lipaemia;** Triglycerides; High carbohydrate diet; Asian Indians; Type 2 diabetes 48, 57
- Protein tyrosine phosphatase;** Bradykinin B2 receptor; Insulin receptor; IRS-1; PI 3-kinase 48, 155
- Psychiatric disorders;** Insulin-dependent diabetes mellitus; Metabolic control; Psychosocial functioning 48, 177
- Psychosocial functioning;** Insulin-dependent diabetes mellitus; Psychiatric disorders; Metabolic control 48, 177

Rats; Bone density; Ovariectomy; Diabetes; Osteoporosis 48, 1

Renal biopsy; Diabetic nephropathy; Immunoglobulin A nephropathy 48, 113

Retinal blood flow; Diabetic retinopathy; Endothelins; Endothelin receptors galactosemia 48, 75

Retinopathy; Type 1 diabetes; Complications; Asian Indians; Nephropathy; Neuropathy; Coronary heart diseases 48, 51

Screening; Gestational diabetes; Polynesian 48, 217

Severe retinopathy; Birth weight; Fetal growth; Type 1 diabetes 48, 61

TNF- α ; MCP-1; Endothelial cells; Troglitazone 48, 171

Transaminases; HCV infection; HBV infection; Type 2 diabetes 48, 147

Triglycerides; Postprandial lipaemia; High carbohydrate diet; Asian Indians; Type 2 diabetes 48, 57

tRNA-Leu; Mitochondrial DNA; GDM; Mutations; ND1 gene 48, 29

Troglitazone; MCP-1; Endothelial cells; TNF- α 48, 171

Type 1 diabetes; Birth weight; Fetal growth; Severe retinopa-

thy 48, 61

Type 2 diabetes; Cardiac autonomic neuropathy; Nephropathy; Neuropathy 48, 211

Type 1 diabetes; Complications; Asian Indians; Retinopathy; Nephropathy; Neuropathy; Coronary heart diseases 48, 51

Type 2 diabetes; HCV infection; HBV infection; Transaminases 48, 147

Type 2 diabetes; Microvascular complications; Intensive glycemic control; Multiple insulin injection treatment; Cost-effectiveness 48, 201

Type 2 diabetes; Triglycerides; Postprandial lipaemia; High carbohydrate diet; Asian Indians 48, 57

Type 2 diabetes; Type I procollagen; Diabetic nephropathy; Diabetic retinopathy; Osteocalcin 48, 23

Type I procollagen; Diabetic nephropathy; Diabetic retinopathy; Osteocalcin; Type 2 diabetes 48, 23

Visceral epithelial cells; Platelet-derived growth factor; Diabetic nephropathy; Immunohistochemistry; Mesangial cells 48, 87

Weight bearing index; Obesity; Grip strength; Leg strength; Body composition 48, 15

